文献库搜索 | GeneLibs

Landry(ML),Malhotra(S),Beresini(M),Chan(C)... J Med Chem 2026-03-12

Mutant KRAS is highly prevalent in human cancer and has been actively pursued as a target for drug discovery. Much progr...

Condakes(ML),Civiello(RL),Lakkaraju(SK),Sl... J Med Chem 2026-03-12

...KRASG12C inhibitors. Using structure-based design augmented with computational models, trajectories were identified that...

Endres(NF),Do(S),Mroue(R),Terrett(JA),Saab... J Med Chem 2026-03-12

...KRAS G12C inhibitors in vitro and shows robust tumor growth inhibition in multiple KRAS G12C-positive cell lines.

Khawaja(MR),Jameson(G),Cridebring(D),Shann... J Immunother Precis Oncol 2026-02-00

Prognosis of metastatic pancreatic cancer remains poor. KRAS mutations are common in pancreatic cancer and are an attrac...

Zhang(Y),Tian(Y),Wei(X),Bai(L),Song(M),Guo... Front Immunol None

...KRAS mutant subtypes and co-mutation patterns. However, validation of these findings is warranted through prospective, m...

De Boni(L),Claridge(S),Nath(S),Tofani(K),S... iScience 2026-03-20

...KRAS-mutant cancer models, trametinib treatment caused dysregulation of the purine biosynthetic pathway driven by reduct...

Shimizu(H),Niwa(T) Toxins (Basel) 2026-01-30

...KRAS-mutated tumors. We also discuss the repurposing of the oral adsorbent AST-120 and emerging bacteriophage therapies ...

Okuda(M),Kawasumi(R),Tanaka(K),Hirota(K) Biomolecules 2026-01-28

...KRASA146T/+ or KRASG12V/+ exhibited increased replication stress compared to KRAS wild-type cells. Strikingly, KRASA146T...

Hwang(HH),Lee(SY),Lee(C),Lee(JY),Ko(SG),Ch... Signal Transduct Target The... 2026-03-02

...Kras-driven mouse lung cancer model revealed that adenoviral CMV-Cre-mediated Gpr54 deletion attenuated NSCLC developmen...

Ndzinisa(M),Altaye(BM),Sher(YP) Kaohsiung J Med Sci 2026-03-02

...KRAS-driven cancers, where persistent oncogenic signaling enhances SG formation and stability, making these condensates ...